| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | 350-NS-010/CF | |||
| Carrier Free | 350-NS-050/CF | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | 350-NS-050/CF | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | 460-SD-010/CF | |||
| Carrier Free | 460-SD-050/CF | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | 460-SD-050/CF | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB310-SP | |||
| Carrier Free | MAB310-500 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF-310-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-12221-0.025mg | |||
![CXCR4 and CXCL12 expression in DLBCL. (a) Expression analysis of CXCR4 and CXCL12 in non-neoplastic control germinal center B cells (GC-B) and diffuse large B cell lymphoma cells (DLBCL) consisting of DLBCL-NGCB and DLCBL-GCB, by RQ-PCR. GCB-DLBCL were further subdivided into primary (DLBCL-pGCB) and transformed DLBCL (DLBCL-pGCB) originating from follicular lymphoma. (b) Expression analysis of CXCR4 and CXCL12 in DLBCL samples with early (stage 1) and advanced stage (stage 2–4) (left graphs) and DLBCL samples with and without bone marrow infiltration (right graphs) by RQ-PCR. (c) Probability of 5-year-survival in DLBCL patients (our cohort left panel and the cohort of Lenz et al. right [20]) stratified by the third quartile of CXCR4 expression, respectively. (d) Representative immunohistochemical stains of CXCR4 (I–III) and CXCL12 (IV–VI) on DLBCL samples (magnification 20×). mRNA expression levels were calculated as a relative expression in comparison to the GC-B cells. All images were captured using an Olympus BX51 microscope and an Olympus E-330 camera. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31554271), licensed under a CC-BY license. Not internally tested by R&D Systems.](http://images.novusbio.com/fullsize/mab350_human-mouse-cxcl12-sdf-1-mab-clone-79018-41202410331984.jpg)
![N/A CXCL12/SDF-1 alpha [HRP]](http://images.novusbio.com/fullsize2/DATA_CXCL12_SDF1_alpha_DSA00_ELISA_819.jpg "N/A CXCL12/SDF-1 alpha [HRP]")
![N/A CXCL12/SDF-1 alpha [HRP]](http://images.novusbio.com/fullsize2/CXCL12_DSA00_ELISA_177.jpg)
![N/A CXCL12/SDF-1 alpha [HRP]](http://images.novusbio.com/fullsize2/DATA_CXCL12_SDF1_alpha_MCX120_ELISA_962.jpg "N/A CXCL12/SDF-1 alpha [HRP]")
![N/A CXCL12/SDF-1 alpha [HRP]](http://images.novusbio.com/fullsize2/CXCL12_MCX120_ELISA_257.jpg)
![N/A CXCL12/SDF-1 [Biotin]](http://images.novusbio.com/fullsize2/DATA_CXCL12_DY350_ELISA_1951.jpg "N/A CXCL12/SDF-1 [Biotin]")
![N/A CXCL12/SDF-1 [Biotin]](http://images.novusbio.com/fullsize2/DATA_CXCL12_DY460_ELISA_2043.jpg "N/A CXCL12/SDF-1 [Biotin]")
![Immunohistochemistry-Frozen: CXCL12/SDF-1 Antibody (MM0211-9N26) [NBP2-12221] - Staining in human uterus tissue.](http://images.novusbio.com/fullsize/CXCL12-SDF-1-Antibody-MM0211-9N26-Immunohistochemistry-Frozen-NBP2-12221-img0004.jpg "Immunohistochemistry-Frozen: CXCL12/SDF-1 Antibody (MM0211-9N26) [NBP2-12221] - Staining in human uterus tissue.")
![Immunohistochemistry-Paraffin: CXCL12/SDF-1 Antibody (MM0211-9N26) [NBP2-12221] - CXCL12/SDF1 in sheep bone marrow. Image from verified customer review.](http://images.novusbio.com/fullsize/CXCL12-SDF-1-Antibody-MM0211-9N26-Immunohistochemistry-Paraffin-NBP2-12221-img0002.jpg)
![Immunohistochemistry-Paraffin: CXCL12/SDF-1 Antibody (MM0211-9N26) [NBP2-12221] - 10% Buffer formalin fixed and parffine embedded human placetal tissue section (4um) is subjected IHC staining using NBP2-12221. Tissue section was pretreated in citric buffer (pH 6.0) with microwave for antige retrieval before IHC is applied.](http://images.novusbio.com/fullsize/CXCL12-SDF-1-Antibody-MM0211-9N26-Immunohistochemistry-Paraffin-NBP2-12221-img0003.jpg)